MIST
Milestone Pharmaceuticals Inc.
Price Chart
Latest Quote
$1.27
-0.03 (-2.31%)
Current Price
| Previous Close | $1.30 |
| Open | $1.30 |
| Day High | $1.31 |
| Day Low | $1.26 |
| Volume | 727,781 |
Stock Information
| Shares Outstanding | 124.50M |
| Total Debt | $137.33M |
| Cash Equivalents | $184.22M |
| Revenue | $1.78M |
| Net Income | $-68.36M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $158.11M |
| EPS (TTM) | $-0.64 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $127.58M |
| Sales | $1.78M |
| Income | $-68.36M |
| Book/sh | $0.27 |
| Cash/sh | $1.48 |
| Employees | 38 |
Financial Ratios
| Quick Ratio | 9.03 |
| Current Ratio | 9.18 |
| Debt/Eq | 380.95 |
Returns & Margins
| ROA | -31.92% |
| ROE | -456.88% |
| Gross Margin | 99.21% |
| Operating Margin | -9942.44% |
Ownership
| Insider Ownership | 2.46% |
| Institutional Ownership | 34.69% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.22 |
| P/S | 88.63 |
| P/B | 4.72 |
Analyst Data
| Recommendation | none |
| Target Price | $6.33 |
Technical Indicators
| SMA20 | $1.30 |
| SMA50 | $1.61 |
| SMA200 | $1.86 |
| RSI | 48.28 |
| ATR | 0.0727 |
| Shares Float | 116.91M |
| Short Float | 7.43% |
| Short Ratio | 6.41 |
| Volatility | 0.96 |
| Rel Volume | 0.57 |
Performance History
| Week | -1.55% |
| Month | -9.93% |
| Quarter | +9.48% |
| 6 Months | -40.93% |
| YTD | -38.05% |
| Year | -27.84% |
| 3 Years | -63.71% |
| 5 Years | -78.76% |
| 10 Years | -91.74% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $1.27 | 727,781 |
| 2026-06-23 | $1.30 | 1,433,900 |
| 2026-06-22 | $1.31 | 1,771,900 |
| 2026-06-18 | $1.30 | 1,338,100 |
| 2026-06-17 | $1.31 | 2,350,700 |
| 2026-06-16 | $1.29 | 1,126,500 |
| 2026-06-15 | $1.31 | 1,929,600 |
| 2026-06-12 | $1.27 | 685,800 |
| 2026-06-11 | $1.27 | 1,058,100 |
| 2026-06-10 | $1.22 | 905,200 |
| 2026-06-09 | $1.21 | 812,900 |
| 2026-06-08 | $1.23 | 1,485,600 |
| 2026-06-05 | $1.23 | 2,424,400 |
| 2026-06-04 | $1.29 | 884,700 |
| 2026-06-03 | $1.28 | 820,700 |
| 2026-06-02 | $1.32 | 1,200,700 |
| 2026-06-01 | $1.36 | 1,312,200 |
| 2026-05-29 | $1.42 | 519,700 |
| 2026-05-28 | $1.44 | 723,800 |
| 2026-05-27 | $1.40 | 2,236,700 |
| 2026-05-26 | $1.40 | 1,265,600 |
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
đ° Latest News
Milestone (MIST) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-06-01T14:31:23Z
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability
Simply Wall St. âĸ 2026-05-15T10:49:38Z
Milestone Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-14T00:44:19Z
Milestone Pharmaceuticals Inc (MIST) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com âĸ 2026-05-13T23:00:56ZWhy Milestone Pharmaceuticals Stock Wilted on Wednesday
Motley Fool âĸ 2026-05-13T22:16:58Z
Milestone Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-13T18:09:23Z
Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Benzinga âĸ 2026-05-13T13:40:07Z
Milestone Pharmaceuticals shares plunge after CARDAMYST revenue misses expectations (MIST)
InvestorsHub âĸ 2026-05-13T13:34:27Z
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-13T12:20:03Z
Earnings Scheduled For May 13, 2026
Benzinga âĸ 2026-05-13T11:11:36Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $1,546,000 | $0 | $1,000,000 | $5,000,000 |
| Operating Revenue | $1,546,000 | $0 | $1,000,000 | $5,000,000 |
| Expenses | ||||
| Interest Expense | $3,838,000 | $3,581,000 | $2,554,000 | $0 |
| Total Expenses | $63,686,000 | $42,102,000 | $62,098,000 | $64,642,000 |
| Net Non Operating Interest Income Expense | $-918,000 | $583,000 | $1,413,000 | $1,254,000 |
| Interest Expense Non Operating | $3,838,000 | $3,581,000 | $2,554,000 | $0 |
| Operating Expense | $63,686,000 | $42,102,000 | $62,098,000 | $64,642,000 |
| Selling And Marketing Expense | $28,304,000 | $11,003,000 | $15,114,000 | $9,095,000 |
| General And Administrative Expense | $17,274,000 | $16,742,000 | $15,932,000 | $15,718,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Net Interest Income | $-918,000 | $583,000 | $1,413,000 | $1,254,000 |
| Interest Income | $2,920,000 | $4,164,000 | $3,967,000 | $1,254,000 |
| Normalized Income | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Net Income From Continuing And Discontinued Operation | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Total Operating Income As Reported | $-62,140,000 | $-42,102,000 | $-61,098,000 | $-59,642,000 |
| Net Income Common Stockholders | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Net Income | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Net Income Including Noncontrolling Interests | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Net Income Continuous Operations | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Pretax Income | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Interest Income Non Operating | $2,920,000 | $4,164,000 | $3,967,000 | $1,254,000 |
| Operating Income | $-62,140,000 | $-42,102,000 | $-61,098,000 | $-59,642,000 |
| Per Share | ||||
| Diluted EPS | $-0.75 | $-0.67 | $-1.39 | $-1.38 |
| Basic EPS | $-0.75 | $-0.67 | $-1.39 | $-1.38 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-59,106,000 | $-37,833,000 | $-57,039,000 | $-58,299,000 |
| Reconciled Depreciation | $114,000 | $105,000 | $92,000 | $89,000 |
| EBITDA (Bullshit earnings) | $-59,106,000 | $-37,833,000 | $-57,039,000 | $-58,299,000 |
| EBIT | $-59,220,000 | $-37,938,000 | $-57,131,000 | $-58,388,000 |
| Diluted Average Shares | $83,882,800 | $62,210,702 | $42,955,779 | $42,450,316 |
| Basic Average Shares | $83,882,800 | $62,210,702 | $42,955,779 | $42,450,316 |
| Diluted NI Availto Com Stockholders | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Research And Development | $18,108,000 | $14,357,000 | $31,052,000 | $39,829,000 |
| Selling General And Administration | $45,578,000 | $27,745,000 | $31,046,000 | $24,813,000 |
| Other Gand A | $17,274,000 | $16,742,000 | $15,932,000 | $15,718,000 |
| Tax Provision | - | - | - | - |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $41,769,000 | $13,147,000 | $16,771,000 | $66,348,000 |
| Total Assets | $113,561,000 | $75,499,000 | $75,226,000 | $74,483,000 |
| Total Non Current Assets | $1,640,000 | $1,573,000 | $2,194,000 | $2,680,000 |
| Current Assets | $111,921,000 | $73,926,000 | $73,032,000 | $71,803,000 |
| Prepaid Assets | $1,805,000 | $1,840,000 | $3,178,000 | $6,005,000 |
| Inventory | $648,000 | $0 | - | - |
| Receivables | $3,508,000 | $2,391,000 | $3,851,000 | $1,213,000 |
| Other Receivables | $1,713,000 | $676,000 | $2,416,000 | $6,000 |
| Taxes Receivable | $1,599,000 | $1,111,000 | $907,000 | $592,000 |
| Accrued Interest Receivable | $196,000 | $604,000 | $528,000 | $615,000 |
| Cash Cash Equivalents And Short Term Investments | $105,960,000 | $69,695,000 | $66,003,000 | $64,585,000 |
| Cash And Cash Equivalents | $73,046,000 | $25,314,000 | $13,760,000 | $7,636,000 |
| Debt | ||||
| Total Debt | $58,377,000 | $54,797,000 | $51,775,000 | $2,491,000 |
| Long Term Debt And Capital Lease Obligation | $57,730,000 | $54,226,000 | $51,229,000 | $1,996,000 |
| Long Term Debt | $57,191,000 | $53,352,000 | $49,772,000 | - |
| Current Debt And Capital Lease Obligation | $647,000 | $571,000 | $546,000 | $495,000 |
| Net Debt | - | $28,038,000 | $36,012,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $71,792,000 | $62,352,000 | $58,455,000 | $8,135,000 |
| Total Non Current Liabilities Net Minority Interest | $57,813,000 | $54,226,000 | $51,229,000 | $1,996,000 |
| Other Non Current Liabilities | $83,000 | - | - | - |
| Current Liabilities | $13,979,000 | $8,126,000 | $7,226,000 | $6,139,000 |
| Other Current Liabilities | $43,000 | - | - | - |
| Payables And Accrued Expenses | $10,831,000 | $5,054,000 | $5,968,000 | $3,071,000 |
| Payables | $5,645,000 | $1,932,000 | $3,981,000 | $2,263,000 |
| Accounts Payable | $5,645,000 | $1,932,000 | $3,981,000 | $2,263,000 |
| Other Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $41,769,000 | $13,147,000 | $16,771,000 | $66,348,000 |
| Total Equity Gross Minority Interest | $41,769,000 | $13,147,000 | $16,771,000 | $66,348,000 |
| Stockholders Equity | $41,769,000 | $13,147,000 | $16,771,000 | $66,348,000 |
| Other Equity Interest | $55,649,000 | $53,076,000 | $48,459,000 | $34,352,000 |
| Retained Earnings | $-430,603,000 | $-367,545,000 | $-326,026,000 | $-266,341,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $106,236,344 | $53,353,984 | $33,483,111 | $34,286,002 |
| Share Issued | $106,236,344 | $53,353,984 | $33,483,111 | $34,286,002 |
| Tangible Book Value | $41,769,000 | $13,147,000 | $16,771,000 | $66,348,000 |
| Invested Capital | $98,960,000 | $66,499,000 | $66,543,000 | $66,348,000 |
| Working Capital | $97,942,000 | $65,800,000 | $65,806,000 | $65,664,000 |
| Capital Lease Obligations | $1,186,000 | $1,445,000 | $2,003,000 | $2,491,000 |
| Total Capitalization | $98,960,000 | $66,499,000 | $66,543,000 | $66,348,000 |
| Additional Paid In Capital | $64,104,000 | $39,568,000 | $33,834,000 | $24,437,000 |
| Capital Stock | $352,619,000 | $288,048,000 | $260,504,000 | $273,900,000 |
| Common Stock | $352,619,000 | $288,048,000 | $260,504,000 | $273,900,000 |
| Long Term Capital Lease Obligation | $539,000 | $874,000 | $1,457,000 | $1,996,000 |
| Current Capital Lease Obligation | $647,000 | $571,000 | $546,000 | $495,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,458,000 | $2,501,000 | $712,000 | $2,573,000 |
| Current Accrued Expenses | $5,186,000 | $3,122,000 | $1,987,000 | $808,000 |
| Net PPE | $1,640,000 | $1,573,000 | $2,194,000 | $2,680,000 |
| Accumulated Depreciation | $-406,000 | $-291,000 | $-191,000 | $-120,000 |
| Gross PPE | $2,046,000 | $1,864,000 | $2,385,000 | $2,800,000 |
| Leases | $92,000 | $85,000 | $85,000 | $102,000 |
| Other Properties | $1,129,000 | $1,376,000 | $1,917,000 | $2,423,000 |
| Machinery Furniture Equipment | $825,000 | $403,000 | $383,000 | $275,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $32,914,000 | $44,381,000 | $52,243,000 | $56,949,000 |
| Treasury Shares Number | - | - | $0 | - |
| Foreign Currency Translation Adjustments | - | - | - | - |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-49,343,000 | $-28,881,000 | $-46,536,000 | $-52,741,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-49,041,000 | $-28,848,000 | $-46,424,000 | $-52,469,000 |
| Cash Flow From Continuing Operating Activities | $-49,041,000 | $-28,848,000 | $-46,424,000 | $-52,469,000 |
| Operating Gains Losses | - | $8,000 | - | $141,000 |
| Investing Activities | ||||
| Capital Expenditure | $-302,000 | $-33,000 | $-112,000 | $-272,000 |
| Investing Cash Flow | $11,246,000 | $8,283,000 | $4,756,000 | $-57,124,000 |
| Cash Flow From Continuing Investing Activities | $11,246,000 | $8,283,000 | $4,756,000 | $-57,124,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $51,009,000 | $27,258,000 | $0 | $2,630,000 |
| Financing Cash Flow | $85,527,000 | $32,119,000 | $47,792,000 | $3,088,000 |
| Cash Flow From Continuing Financing Activities | $85,527,000 | $32,119,000 | $47,792,000 | $3,088,000 |
| Net Common Stock Issuance | $51,009,000 | $27,258,000 | $0 | $2,630,000 |
| Common Stock Issuance | $51,009,000 | $27,258,000 | $0 | $2,630,000 |
| Net Other Financing Charges | - | - | $-2,782,000 | - |
| Other | ||||
| End Cash Position | $73,046,000 | $25,314,000 | $13,760,000 | $7,636,000 |
| Beginning Cash Position | $25,314,000 | $13,760,000 | $7,636,000 | $114,141,000 |
| Changes In Cash | $47,732,000 | $11,554,000 | $6,124,000 | $-106,505,000 |
| Proceeds From Stock Option Exercised | $34,518,000 | $4,861,000 | $574,000 | $458,000 |
| Net Investment Purchase And Sale | $11,548,000 | $8,316,000 | $4,868,000 | $-56,852,000 |
| Sale Of Investment | $94,466,000 | $121,870,000 | $142,000,000 | $29,000,000 |
| Purchase Of Investment | $-82,918,000 | $-113,554,000 | $-137,132,000 | $-85,852,000 |
| Net PPE Purchase And Sale | $-302,000 | $-33,000 | $-112,000 | $-272,000 |
| Purchase Of PPE | $-302,000 | $-33,000 | $-112,000 | $-272,000 |
| Change In Working Capital | $2,684,000 | $3,656,000 | $1,243,000 | $-3,262,000 |
| Change In Other Working Capital | $-12,000 | $-17,000 | $18,000 | $81,000 |
| Change In Payables And Accrued Expense | $4,432,000 | $875,000 | $1,036,000 | $-907,000 |
| Change In Prepaid Assets | $29,000 | $1,338,000 | $2,827,000 | $-1,706,000 |
| Change In Inventory | $-648,000 | $0 | - | - |
| Change In Receivables | $-1,117,000 | $1,460,000 | $-2,638,000 | $-730,000 |
| Other Non Cash Items | $3,839,000 | $3,580,000 | $2,554,000 | - |
| Stock Based Compensation | $7,461,000 | $5,776,000 | $9,534,000 | $9,048,000 |
| Amortization Of Securities | $-81,000 | $-454,000 | $-162,000 | $-97,000 |
| Depreciation Amortization Depletion | $114,000 | $105,000 | $92,000 | $89,000 |
| Depreciation And Amortization | $114,000 | $105,000 | $92,000 | $89,000 |
| Depreciation | $114,000 | $105,000 | $92,000 | $89,000 |
| Gain Loss On Sale Of PPE | $0 | $8,000 | $0 | $141,000 |
| Net Income From Continuing Operations | $-63,058,000 | $-41,519,000 | $-59,685,000 | $-58,388,000 |
| Issuance Of Debt | - | $0 | $50,000,000 | $0 |
| Net Issuance Payments Of Debt | - | $0 | $50,000,000 | $0 |
| Net Long Term Debt Issuance | - | $0 | $50,000,000 | $0 |
| Long Term Debt Issuance | - | $0 | $50,000,000 | $0 |
Fetched: 2026-06-21